carmustine has been researched along with Nausea in 26 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evidence supports olanzapine for prophylaxis of chemotherapy-induced nausea/vomiting (CINV) for highly emetogenic chemotherapy; however, most studies focus on solid malignancies and single-day regimens." | 9.27 | Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig ( Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C, 2018) |
| "To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy." | 9.19 | Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014) |
| " To evaluate possible synergism in the treatment of human multiple myeloma (MM), 23 evaluable patients who had relapsed with standard treatment were treated with cisplatin, BCNU, CTX, and prednisone." | 9.05 | Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. ( Broun, GO; Cohen, HJ; Hiramoto, RN; Petruska, PJ, 1982) |
| "To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation." | 7.83 | Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. ( Clark, SM; Clemmons, AB; DeRemer, DL; Garren, J; Kota, VK; Schaack, L, 2016) |
| "A clinical study of palonosetron was performed to evaluate its efficacy in preventing both acute and delayed emesis after high-dose chemotherapy (HDC) before hematopoietic stem cell transplantation (HSCT) using a historical control group of patients treated with ondansetron as the comparative drug." | 7.75 | Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009) |
| "A therapeutic regimen is described for sedative, analgesic, and anti-emetic effect in patients receiving intra-arterial carmustine (BCNU) for malignant gliomas." | 7.67 | Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion. ( Klein, DS; Klein, PW; Mahaley, MS, 1986) |
| "Evidence supports olanzapine for prophylaxis of chemotherapy-induced nausea/vomiting (CINV) for highly emetogenic chemotherapy; however, most studies focus on solid malignancies and single-day regimens." | 5.27 | Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig ( Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C, 2018) |
| "To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy." | 5.19 | Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014) |
| "We performed a clinical study of a triple-drug combination to evaluate its efficacy to prevent both acute and delayed emesis after high-dose chemotherapy with BEAM (BCNU [carmustine]+etoposide+ARA-C [cytarabine]+melphalan) before hematopoietic stem cell transplantation (HSCT) by comparison with a historical control group of patients treated with dexamethasone (dex) and ondansetron or palonosetron." | 5.15 | A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. ( Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A, 2011) |
| "Both metoclopramide and prochlorperazine in combination with lorazepam and diphenhydramine offer good control of nausea and vomiting although the sedation and low risk for cardiac toxicity limit the regimen to an inpatient setting with close monitoring." | 5.08 | Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. ( Gilbert, CJ; Ohly, KV; Peters, WP; Rosner, G, 1995) |
| " To evaluate possible synergism in the treatment of human multiple myeloma (MM), 23 evaluable patients who had relapsed with standard treatment were treated with cisplatin, BCNU, CTX, and prednisone." | 5.05 | Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. ( Broun, GO; Cohen, HJ; Hiramoto, RN; Petruska, PJ, 1982) |
| "To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation." | 3.83 | Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. ( Clark, SM; Clemmons, AB; DeRemer, DL; Garren, J; Kota, VK; Schaack, L, 2016) |
| "A clinical study of palonosetron was performed to evaluate its efficacy in preventing both acute and delayed emesis after high-dose chemotherapy (HDC) before hematopoietic stem cell transplantation (HSCT) using a historical control group of patients treated with ondansetron as the comparative drug." | 3.75 | Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009) |
| "21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks." | 3.67 | Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984) |
| " We treated 25 consecutive patients (13 pilot patients and 12 protocol patients) with histologically confirmed unresectable grade 3 or 4 malignant gliomas with high-dose BCNU (carmustine) followed by autologous bone marrow transplantation and whole brain irradiation." | 3.67 | Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation. ( Corwin, JA; Daly, MB; de los Reyes, RA; Johnson, DB; Lamaster, D; Mosley, KR; Petty, AM; Pierson, WP; Smith, MT; Thompson, JM, 1987) |
| "Twenty-three patients with metastatic melanoma were treated with combination therapy consisting of dacarbazine (220 mg/m2) and cisplatin (25 mg/m2) iv daily for 3 days every 3 weeks, carmustine (150 mg/m2) iv every 6 weeks, and tamoxifen (10 mg) orally twice daily." | 3.67 | Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF, 1987) |
| "A therapeutic regimen is described for sedative, analgesic, and anti-emetic effect in patients receiving intra-arterial carmustine (BCNU) for malignant gliomas." | 3.67 | Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion. ( Klein, DS; Klein, PW; Mahaley, MS, 1986) |
| "Forty-five malignant lymphoma patients (mean age 38 years, M:F 30:15), undergoing the highly emetogenic regimen BEAM prior to ASCT, were randomized to receive IV granisetron (G) 3 mg once a day, IV tropisetron (T) 5 mg once a day, or IV ondansetron (0) 8 mg twice daily, for six days." | 2.69 | Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. ( Klener, P; Procházka, B; Slabý, J; Trnený, M, 2000) |
| "Fifteen patients with germ cell neoplasms (9 testicular primary, 4 extragonadal, 2 adult teratoma syndrome) with features indicative of a poor prognosis were treated with chemotherapy followed by surgery." | 2.66 | Combination chemotherapy including VP-16 for poor prognosis germ cell neoplasms. ( Bukowski, RM; Montie, JE; Smith, GW, 1988) |
| " The dosage of CCNU was 100 mg/m2 p." | 2.65 | The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. ( Brunner, K; Cuttner, J; Falkson, G; Hansen, HH; Holland, JF; Nissen, NI; Pajak, TF; Selawry, OS; Spurr, CL, 1981) |
| "It is an effective drug in the treatment of malignant melanoma with better response rates in women than in men." | 2.64 | Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. ( Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W, 1976) |
| "Patients with high risk breast carcinoma were conditioned with high dose carmustine, cisplatin, and cyclophosphamide followed by autologous PSCT." | 1.30 | Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma. ( Chap, L; Hecht, JR; Lembo, T, 1997) |
| " The BAD pump was safe and effective in minimizing nausea and vomiting associated with HDC, and thus, eliminated the need for hospitalization for management of chemotherapy-induced nausea and vomiting." | 1.30 | Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. ( Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999) |
| "Twenty-two advanced consecutive thyroid cancer patients with varying histologies were treated with the so called BAP regime which consisted of bleomycin (B) 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv in day 5, and cisplatinum (P) 60 to mg/m2 iv in day 5." | 1.28 | Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. ( Busnardo, B; Casara, D; De Besi, P; Fiorentino, MV; Girelli, ME; Nacamulli, D; Simioni, N; Toso, S; Zorat, P, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (50.00) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Ahern, K | 1 |
| Pham, J | 1 |
| Sanderson, R | 1 |
| Correia De Farias, M | 1 |
| Walsh, K | 1 |
| Clemmons, AB | 2 |
| Orr, J | 1 |
| Andrick, B | 1 |
| Gandhi, A | 1 |
| Sportes, C | 1 |
| DeRemer, D | 1 |
| Xiao, Y | 1 |
| Liu, J | 1 |
| Liu, YC | 1 |
| Huang, XE | 1 |
| Guo, JX | 1 |
| Wei, W | 1 |
| Clark, SM | 1 |
| Schaack, L | 1 |
| Garren, J | 1 |
| DeRemer, DL | 1 |
| Kota, VK | 1 |
| Rzepecki, P | 2 |
| Pielichowski, W | 2 |
| Oborska, S | 2 |
| Barzal, J | 2 |
| Mlot, B | 2 |
| Gawronski, K | 1 |
| Wasko-Grabowska, A | 1 |
| Stewart, DJ | 1 |
| Benoit, B | 1 |
| Richard, MT | 1 |
| Hugenholtz, H | 1 |
| Dennery, J | 1 |
| Russell, N | 1 |
| Peterson, E | 1 |
| Grahovac, Z | 1 |
| Belanger, G | 1 |
| Maroun, JA | 1 |
| DiBella, NJ | 1 |
| Garfield, D | 1 |
| Fink, K | 1 |
| Anderson, P | 1 |
| Speer, J | 1 |
| Murphy, J | 1 |
| Hansen, HH | 1 |
| Selawry, OS | 1 |
| Pajak, TF | 1 |
| Spurr, CL | 1 |
| Falkson, G | 2 |
| Brunner, K | 1 |
| Cuttner, J | 1 |
| Nissen, NI | 1 |
| Holland, JF | 1 |
| Broun, GO | 1 |
| Petruska, PJ | 1 |
| Hiramoto, RN | 1 |
| Cohen, HJ | 1 |
| Gilbert, CJ | 1 |
| Ohly, KV | 1 |
| Rosner, G | 1 |
| Peters, WP | 1 |
| Hecht, JR | 1 |
| Lembo, T | 1 |
| Chap, L | 1 |
| Dix, S | 1 |
| Cord, M | 1 |
| Howard, S | 1 |
| Coon, J | 1 |
| Belt, R | 1 |
| Geller, R | 1 |
| Slabý, J | 1 |
| Trnený, M | 1 |
| Procházka, B | 1 |
| Klener, P | 1 |
| Maranhão, RC | 1 |
| Graziani, SR | 1 |
| Yamaguchi, N | 1 |
| Melo, RF | 1 |
| Latrilha, MC | 1 |
| Rodrigues, DG | 1 |
| Couto, RD | 1 |
| Schreier, S | 1 |
| Buzaid, AC | 1 |
| Johnson, RO | 1 |
| Metter, G | 1 |
| Wilson, W | 1 |
| Hill, G | 1 |
| Krementz, E | 1 |
| Costanzi, JJ | 1 |
| Wasserman, TH | 1 |
| De Besi, P | 1 |
| Busnardo, B | 1 |
| Toso, S | 1 |
| Girelli, ME | 1 |
| Nacamulli, D | 1 |
| Simioni, N | 1 |
| Casara, D | 1 |
| Zorat, P | 1 |
| Fiorentino, MV | 1 |
| Case, DC | 1 |
| Ervin, TJ | 1 |
| Boyd, MA | 1 |
| Redfield, DL | 1 |
| Bukowski, RM | 1 |
| Smith, GW | 1 |
| Montie, JE | 1 |
| Johnson, DB | 1 |
| Thompson, JM | 1 |
| Corwin, JA | 1 |
| Mosley, KR | 1 |
| Smith, MT | 1 |
| de los Reyes, RA | 1 |
| Daly, MB | 1 |
| Petty, AM | 1 |
| Lamaster, D | 1 |
| Pierson, WP | 1 |
| McClay, EF | 1 |
| Mastrangelo, MJ | 1 |
| Bellet, RE | 1 |
| Berd, D | 1 |
| Klein, DS | 1 |
| Klein, PW | 1 |
| Mahaley, MS | 1 |
| Tormey, DC | 1 |
| Gailani, S | 1 |
| Leone, L | 1 |
| van Eden, EB | 1 |
| Falkson, HC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Addition of Olanzapine to Standard CINV Prophylaxis in Hematopoietic Stem Cell Transplant[NCT04535141] | Phase 3 | 91 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Randomized, Placebo Controlled Study of FOND (Fosaprepitant, Ondansetron, Dexamethasone) Versus FOND+O (FOND Plus Olanzapine) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Hematology Patients Receiving Highly Emetogenic Chemotherapy Re[NCT02635984] | Phase 3 | 108 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The total number of rescue medications needed for breakthrough chemotherapy-induced nausea and vomiting were calculated, starting from the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy.~The rescue medication is defined as documented administration of an anti-emetic agent other than those that are scheduled for CINV prophylaxis." (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy ( Days 2-12).
| Intervention | number of rescue medication (Mean) |
|---|---|
| Usual Care | 0.47 |
| Olanzapine | 1.17 |
"The total number of rescue medications needed acute was calculated, starting from the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~The rescue medication is defined as documented administration of an anti-emetic agent other than those that are scheduled for chemotherapy-induced nausea and vomiting (CINV) prophylaxis." (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration. (Up to day 2)
| Intervention | number of rescue medication (Mean) |
|---|---|
| Usual Care | 0.08 |
| Olanzapin | 0.10 |
"Starting with the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~Nausea was assessed using subjects' responses to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea questions. Scale: Never, Rarely, Occasionally, Frequently, Almost constantly.~To meet this endpoint the score reported for the Pro-CTCAE question for nausea frequency cannot exceed rarely in the first 24 hours following receipt of chemotherapy." (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration (Up to day 2)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 44 | 1 |
| Usual Care | 43 | 3 |
The frequency of somnolence was determined as the number of patients who experienced somnolence based on Common Terminology Criteria for Adverse Events version 5 (CTCAE v5). The number of subjects has somnolence during the study period was counted. (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| subjects have somnolence | subjects do not have somnolence | |
| Olanzapine | 1 | 42 |
| Usual Care | 0 | 46 |
The number of emesis episodes in acute phase was defined as the number of subjects with no emesis, 1 emesis, and 2 or more emesis. (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy ( Days 2-12).
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| No emesis episodes | 1 emesis episode | 2 or more emesis episodes | |
| Olanzapine | 36 | 6 | 3 |
| Usual Care | 32 | 9 | 5 |
: The number of subjects who did not experience emesis, starting from the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy. Met endpoint = 0 emesis. (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration. (Up to day 2)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 45 | 0 |
| Usual Care | 45 | 1 |
"Nausea was assessed using subjects' responses to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea questions, starting the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy.~Scale: Never, Rarely, Occasionally, Frequently, Almost constantly.~The number of subjects who experienced never or rarely nausea were considered as met the endpoint while those who experienced occasionally, frequently or almost constantly were considered as not met the endpoint." (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy (Days 2-12).
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 27 | 18 |
| Usual Care | 19 | 27 |
"To determine the number of subjects achieving minimal nausea was defined as the frequency of participants responded to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea question In the last 24 hours, how often did you have nausea? as rarely or less Starting with the first dose of chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~PRO-CTCAE of nausea scale includes categories: Never, Rarely, Occasionally, Frequently, Almost constantly To meet this endpoint the score reported for the Pro-CTCAE question for nausea frequency cannot exceed rarely and the score reported for the Pro-CTCAE question for nausea severity cannot exceed mild" (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Yes | No | |
| Olanzapine | 25 | 20 |
| Usual Care | 15 | 31 |
Prolongation of corrected QTc interval graded as defined in Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Corrected QTc was calculated using Fredericia's Formula. Corrected QT interval (QTc) = QT interval / (60/Heart rate)^0.33. (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy (Days 2- 12).
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | None | |
| Baseline Olanzapine | 4 | 0 | 0 | 0 | 0 | 41 |
| Baseline Usual Care | 3 | 0 | 0 | 0 | 0 | 43 |
| Olanzapine Post-chemo Day 1 | 3 | 0 | 0 | 0 | 0 | 42 |
| Olanzapine- End of Study | 3 | 0 | 1 | 0 | 0 | 41 |
| Usual Care End of Study | 3 | 0 | 1 | 0 | 0 | 42 |
| Usual Care Post-chemo Day 1 | 2 | 0 | 0 | 0 | 0 | 44 |
"The severity of nausea in the delayed phase was defined as the response of the subject to the PRO- CTCAE nausea question.~Starting the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy (PRO-CTCAE) Scale: Never, Rarely, Occasionally, Frequently, Almost constantly~o meet the endpoint, the subject could not have answered a score as higher than mild in the period of time starting 24 hours after the last dose of chemotherapy and continuing until the 5th day following receipt of chemotherapy ." (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 31 | 24 |
| Usual Care | 23 | 23 |
Overall percentage of patients who had a complete response (CR) defined as no emesis and minimal nausea (< 25 mm on a 100 mm visual analog scale [VAS]) during the overall assessment period (starting day 1 of chemotherapy and continuing for 5 days after discontinuation of chemotherapy) for the first cycle of chemotherapy. (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 13 |
| Triplet Therapy Plus Olanzapine | 28 |
Reported as acute [chemotherapy days]. All assessment with all VAS < 25 mm on days of chemotherapy (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 33 |
| Triplet Therapy Plus Olanzapine | 39 |
Reported for delayed [5 days after chemotherapy administration] All assessment with all VAS < 25 mm (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 16 |
| Triplet Therapy Plus Olanzapine | 34 |
(CP = no emesis, no breakthrough antiemetic use, no significant nausea). To be reported as overall phases [chemotherapy days plus 5 days after] (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 6 |
| Triplet Therapy Plus Olanzapine | 13 |
Complete response (no emesis and no more than minimal nausea, defined as < 25 mm on a 100 mm visual analog scale [VAS]) in acute phase (days of chemotherapy) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 31 |
| Triplet Therapy Plus Olanzapine | 39 |
Complete response (no emesis and no more than minimal nausea, defined as < 25 mm on a 100 mm visual analog scale [VAS]) in delayed phase (5 days after chemotherapy) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 15 |
| Triplet Therapy Plus Olanzapine | 31 |
No nausea (all VAS <5 mm) in overall assessment period (days of chemotherapy plus five days after) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 6 |
| Triplet Therapy Plus Olanzapine | 18 |
Reported for overall phases [chemotherapy days plus 5 days after] where all VAS < 25 mm (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 14 |
| Triplet Therapy Plus Olanzapine | 30 |
12 trials available for carmustine and Nausea
| Article | Year |
|---|---|
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazin | 2014 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dex | 2011 |
The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study.
Topics: Adult; Carmustine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration S | 1981 |
Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Bone Marrow; Carmustine; Cisplatin; Clinical Trials as | 1982 |
Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combine | 1995 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Th | 2000 |
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Femal | 1976 |
DTIC (NSC-45388) studies in the southwest oncology group.
Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Co | 1976 |
Waldenström's macroglobulinemia: long-term results with the M-2 protocol.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dru | 1991 |
Combination chemotherapy including VP-16 for poor prognosis germ cell neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as | 1988 |
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea in colon cancer.
Topics: Alopecia; Amides; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dr | 1974 |
14 other studies available for carmustine and Nausea
| Article | Year |
|---|---|
The nutritional impact of CD19-targeted CAR-T therapy versus BEAM chemotherapy for adult patients with lymphoma.
Topics: Adult; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Human | 2023 |
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
Topics: Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Huma | 2009 |
Treatment of malignant gliomas in adults with BCNU plus metronidazole.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Female; Gliobl | 1984 |
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 1984 |
Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Comb | 1997 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1999 |
Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Survival; Drug Carriers; E | 2002 |
The nitrosoureas: an outline of clinical schedules and toxic effects.
Topics: Administration, Oral; Bone Marrow; Capsules; Carmustine; Humans; Injections, Intravenous; Lomustine; | 1976 |
Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethas | 1991 |
Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1987 |
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1987 |
Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Diazepam; Droperidol; Drug Therapy, Comb | 1986 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |